Fengmin Zhao

7PUBLICATIONS
42CO-AUTHORS
Molecular targetsEpidemiological modellingCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 11, 2026
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.

|May 30, 2026
Impact of patient-reported taxane-induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG-ACRIN EAZ171.

|Oct 22, 2025
Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments.

John Devin Peipert, Shaili Ganatra, Fengmin Zhao

|Apr 29, 2025
A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study.

Amy S Clark, Fengmin Zhao, Paula Klein

|Nov 02, 2021
Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events.

Edward H Ip, Santiago Saldana, Kathy D Miller

|Dec 02, 2020
Impact of insurance and neighborhood socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer.

Samilia Obeng-Gyasi, Anne O'Neill, Fengmin Zhao

Pageof 2

Frequent Collaborators

3 joint publications

John Devin Peipert

2 joint publications

Lynne I Wagner

2 joint publications

Ruth C Carlos

2 joint publications

Edward H Ip